Merck reached a deal to acquire an antibody drug for over 8 billion dollars.

On March 31, biopharmaceutical company Infinimmune announced an agreement with Merck, targeting multiple disease targets to develop various antibodies. The total value of this deal is expected to be up to approximately $838 million. Infinimmune stated that it will use its proprietary platform for screening human immune cells and identifying naturally occurring antibodies, and then further develop these antibodies using artificial intelligence tools. Merck will have the exclusive rights to develop and commercialize the resulting antibody candidate drugs.